EEF1A2 and ovarian carcinoma: This vaccine was then improved, producing a unimolecular pentavalent vaccine containing the antigens Globo-H, GM2, STn, TF, and Tn conjugated to KLH, [306], and it was evaluated in a phase I clinical trial in ovarian cancer patients (NCT01248273) [80].